zolinza/vorinostat
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Conditions
Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Trial Timeline
Mar 1, 2012 → Mar 24, 2017
NCT ID
NCT01422499About zolinza/vorinostat
zolinza/vorinostat is a phase 1/2 stage product being developed by Merck for Children With Relapsed Solid Tumor, Lymphoma or Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01422499. Target conditions include Children With Relapsed Solid Tumor, Lymphoma or Leukemia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01422499 | Phase 1/2 | Completed |
Competing Products
20 competing products in Children With Relapsed Solid Tumor, Lymphoma or Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Quizartinib + Etoposide + Dexrazoxane + Mitoxantrone + Cytarabine + Methotrexate + Daunorubicin + Fludarabine | Daiichi Sankyo | Phase 2 | 52 |
| RSS0393 Ointment | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Exenatide Once Weekly + Placebo | AstraZeneca | Phase 3 | 77 |
| MEDI3250 + Placebo | AstraZeneca | Phase 3 | 77 |
| MEDI3250 | AstraZeneca | Phase 3 | 77 |
| Budesonide Formoterol Drug Combination + nebulisation of terbutaline | AstraZeneca | Phase 3 | 77 |
| Saizen® A + Saizen® B | Merck | Phase 3 | 77 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| Hydroxyurea | Novartis | Phase 3 | 77 |
| Norditropin® FlexPro® | Novo Nordisk | Pre-clinical | 22 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| Somapacitan | Novo Nordisk | Pre-clinical | 22 |
| Voxelotor | Pfizer | Phase 2 | 51 |
| Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citrate | Pfizer | Phase 3 | 76 |
| Copanlisib (BAY806946) | Bayer | Phase 1/2 | 38 |
| Eptinezumab | Lundbeck | Phase 1 | 30 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |